Osteoarthritis injection may affect metabolism in diabetes

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Intra-articular corticosteroid injection (IACI) of betamethasone (eg, Celestone Soluspan) for knee osteoarthritis increases blood glucose, insulin, and insulin resistance in patients with type 2 diabetes (T2D).

Why this matters

  • Clinicians prescribing IACI should be aware of and monitor its effects on metabolism in patients with T2D.

Key results

  • Blood glucose (P=.004), insulin (P=.004), and insulin resistance (P=.003) were significantly higher than baseline at 1 day after IACI, and all returned to normal levels by day 8.
  • Control patients did not show significant changes in blood glucose, insulin, or insulin resistance between baseline, day 1, and day 8.
  • There were no significant differences in demographics between the control group and the treatment group.

Study design

  • 10 patients with noninsulin-treated T2D and painful osteoarthritis were given IACI of 1 mL of depot betamethasone.
  • Researchers measured fasting blood glucose and fasting blood insulin levels just before IACI and at 1 and 8 days after, and compared with age- and sex-matched control patients with T2D.
  • Funding: None disclosed.


  • Small sample size.